Organic Process Research & Development 2002, 6, 814−816
A Practical Synthesis of L-Valyl-pyrrolidine-(2R)-boronic Acid: Efficient
Recycling of the Costly Chiral Auxiliary (+)-Pinanediol
Frank S. Gibson,* Ambarish K. Singh, Maxime C. Soumeillant, Percy S. Manchand, Michael Humora, and
David R. Kronenthal
Process Research and DeVelopment, The Bristol-Myers Squibb Pharmaceutical Research Institute, One Squibb DriVe,
New Brunswick, New Jersey 08903, U.S.A.
Abstract:
A practical synthesis of L-valyl-pyrrolidine-(2R)-boronic acid
(1) is detailed. A previously disclosed synthesis of 1 (Snow, R.;
Kelly, T. R.; Adams, J.; Coutts, S.; Perry, C. (Boehringer
Ingelheim Pharmaceuticals, Inc.). WO 93/10127, 1993) was
significantly improved by developing an efficient process for
recycling the costly chiral auxiliary (+)- pinanediol.
Figure 1. L-Valyl-pyrrolidine-(2R)-boronic acid.
which was highly crystalline and exhibited good physico-
chemical properties.
Introduction
Peptides containing boronic acid analogues of amino acids
have recently been investigated for their anticancer and serine
protease inhibiting activities.2 Evidence suggests that these
types of compounds could also be useful as immunosup-
pressants.3 The proline surrogate pyrrolidine-2-boronic acid
imparts significant proteinase inhibitory activity towards
bacteria when present as a C-terminus residue in certain
peptides.4 Our interest was focused on developing a practical
synthesis of L-valyl-pyrrolidine-(2R)-boronic acid 1 (Figure
1). This compound is an immunostimulant and may serve
as a potential adjuvant to standard chemotherapy.
Scale-up of the reported synthesis of 11 was challenging
due to the use of a number of hazardous reagents as well as
inefficient and tedious purification steps. Furthermore,
expensive (+)-pinanediol was utilized as an unrecovered
resolving agent. At a bulk price of nearly $10 000 per kg,
and without an efficient recycle in place, this material initially
comprised >90% of the overall API cost. Because our
production of 1 was projected to be less than 2 kg/yr due to
microgram-dosing levels, it was unlikely the price of bulk
pinanediol could be significantly reduced, as would normally
be the case for typical manufacturing volumes. Additionally,
the HCl salt 1a was not suitable for further development
because of its amorphous and deliquescent nature. An
extensive search for a more suitable salt form eventually led
to the selection of methanesulfonic acid (MSA) salt 1b,
Results and Discussion
The previously disclosed synthesis1 of the key intermedi-
ate 6a was demonstrated on >100-g scale with several
modifications as outlined in Scheme 1. THF was an
acceptable substitute for diethyl ether as the solvent in the
lithiation of 2, and TMEDA was not required as an additive.
With appropriate precautions, we were able to safely
handle sec-butyllithium on multiliter scale. Attempts to
employ a less hazardous reagent for the R-metalation were
unsuccessful.5 The boronic acid 3 was condensed with (+)-
pinanediol, and after removal of the Boc group under acidic
conditions, 6a was obtained as a crystalline solid with
diastereomeric excess (de) of 92%. A single recrystallization
from IPA produced 6a with de >99%.1b Initial supplies of
HCl salt 1a were prepared using the previously reported
synthesis as outlined in Scheme 2. EDAC-mediated coupling
of 6a with Boc-valine gave 8a, which was subsequently
deprotected using anhydrous HCl. The pinanediol auxiliary
was then removed by an exchange process using phenylbo-
ronic acid. Salt-exchange to the more desirable MSA salt
1b was accomplished by the addition of 1 equiv of MSA to
a solution of 1a in acetone-water, resulting in the crystal-
lization of 1b.
While preparing the initial supplies of the API, we
recognized that to devise a safe, scalable, and cost-effective
synthesis of the preferred salt form 1b, we needed to address
the following issues: (1) recycling of the (+)-pinanediol to
reduce the overall cost of goods, (2) elimination of other
costly or environmentally unfriendly reagents and solvents
(e.g., EDAC and dichloromethane), and (3) development of
a process for the direct isolation of 1b without going through
1a.
(1) (a) Snow, R.; Kelly, T. R.; Adams, J.; Coutts, S.; Perry, C. (Boehringer
Ingelheim Pharmaceuticals, Inc.). WO 93/10127, 1993. (b) Kelly, T. A.;
Fuchs, V. U.; Perry, C. W.; Snow, R. J. Tetrahedron 1993, 1009. (c)
Martina, S.; Enkelmen, V.; Wegner, G.; Schluter, A. D. Synthesis 1991,
613.
(2) (a) Matteson, D. S.; Sadhu, H. M.; Lienhard, G. E. J. Am. Chem. Soc.
1981, 5241. (b) Kettner, C. A.; Shenvi, A. B. J. Biol. Chem. 1984, 15106.
(c) Kinder, K. H.; Katzenellenbogen, J. A. J. Med. Chem. 1985, 1917.
(3) Flentke, G. R.; Munoz, E.; Huber, B. T.; Plaut, A. G.; Kettner, C. A.;
Bachovchin, W. W. Proc. Natl. Acad. Sci. U.S.A. 1991, 1556.
(4) Bachovchin, W. W.; Plaut, A. G.; Flentke, G. R.; Lynch, M.; Kettner, C.
A. J. Biol. Chem. 1990, 3738.
(5) (a) Beak, P.; Zajdel, W. J.; Reitz, D. B. Chem. ReV. 1984, 471. (b) Meyers,
A. I. Aldrichimica Acta 1985, 59. (c) Comins, D. L.; Weglarz, M. A. J.
Org. Chem. 1988, 4437. Beak, P.; Lee, W. K. J. Org. Chem. 1990, 55, 8.
814
•
Vol. 6, No. 6, 2002 / Organic Process Research & Development
10.1021/op025587b CCC: $22.00 © 2002 American Chemical Society
Published on Web 10/23/2002